Tivozanib
≥99.5%
- Product Code: 67654
Alias:
Related CAS number: 475108-18-0
CAS:
682745-41-1
| Molecular Weight: | 509.34 g./mol | Molecular Formula: | C₂₂H₂₂Cl₂N₄O₆ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD34184484 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Tivozanib is primarily used as a targeted therapy in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By inhibiting these receptors, Tivozanib helps to block the formation of new blood vessels that supply tumors, thereby slowing down tumor growth and spread. Its application is particularly beneficial for patients who have not responded well to other treatments, offering a more focused approach to managing the disease. The drug is administered orally, making it convenient for patients to use as part of their ongoing cancer treatment regimen. Clinical studies have shown that Tivozanib can improve progression-free survival in patients with advanced RCC, making it a valuable option in the oncology field.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White Powder |
| PURITY | 99.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿5,600.00 |
+
-
|
| 0.025 | 10-20 days | ฿18,500.00 |
+
-
|
| 0.100 | 10-20 days | ฿42,200.00 |
+
-
|
| 0.500 | 10-20 days | ฿99,990.00 |
+
-
|
Tivozanib
Tivozanib is primarily used as a targeted therapy in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By inhibiting these receptors, Tivozanib helps to block the formation of new blood vessels that supply tumors, thereby slowing down tumor growth and spread. Its application is particularly beneficial for patients who have not responded well to other treatments, offering a more focused approach to managing the disease. The drug is administered orally, making it convenient for patients to use as part of their ongoing cancer treatment regimen. Clinical studies have shown that Tivozanib can improve progression-free survival in patients with advanced RCC, making it a valuable option in the oncology field.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :